Skip to content

Study · Randomized controlled trial · n = 48 · 2020

5 results

Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial.

Wegeberg AL, Hansen CS, Farmer AD, Karmisholt JS, Drewes AM, Jakobsen PE, Brock B, Brock C

United European gastroenterology journal9 May 2020Cited by 24 (Europe PMC)

PMID32390563 (opens in a new tab)PMCIDPMC7437086 (opens in a new tab)DOI10.1177/2050640620925968 (opens in a new tab)PepBankPUB-32390563
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes and polyneuropathy, liraglutide shortened large bowel transit time versus placebo.

    In plain wordsIn adults with type 1 diabetes and nerve damage, liraglutide sped up transit through the large bowel compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseLarge bowel transit time
    Study

    n = 48

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Reduction in large bowel transit time
    31.7%
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide treatment reduced large bowel transit time (31.7%, p = 0.04) and decreased motility index (6.1%, p = 0.04) compared to placebo, whereas the groups did not differ in gastric emptying or small-bowel transit times.
    1 context sentence
    Summary · context
    A total of 48 adults with type 1 diabetes and confirmed distal symmetric polyneuropathy were randomised to receive liraglutide 1.8 mg/day or placebo for 26 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes and polyneuropathy, liraglutide decreased the motility index versus placebo.

    In plain wordsIn adults with type 1 diabetes and nerve damage, liraglutide lowered the gut motility index compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMotility index
    Study

    n = 48

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Decrease in motility index
    6.1%
    liraglutide vs placebo

    Source sentences

    Summary
    Liraglutide treatment reduced large bowel transit time (31.7%, p = 0.04) and decreased motility index (6.1%, p = 0.04) compared to placebo, whereas the groups did not differ in gastric emptying or small-bowel transit times.
    1 context sentence
    Summary · context
    A total of 48 adults with type 1 diabetes and confirmed distal symmetric polyneuropathy were randomised to receive liraglutide 1.8 mg/day or placebo for 26 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes and polyneuropathy, gastric emptying did not differ between liraglutide and placebo.

    In plain wordsIn adults with type 1 diabetes and nerve damage, stomach emptying did not differ between liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeGastric emptying time
    Study

    n = 48

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide treatment reduced large bowel transit time (31.7%, p = 0.04) and decreased motility index (6.1%, p = 0.04) compared to placebo, whereas the groups did not differ in gastric emptying or small-bowel transit times.
    1 context sentence
    Summary · context
    A total of 48 adults with type 1 diabetes and confirmed distal symmetric polyneuropathy were randomised to receive liraglutide 1.8 mg/day or placebo for 26 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 1 diabetes and polyneuropathy, small-bowel transit time did not differ between liraglutide and placebo.

    In plain wordsIn adults with type 1 diabetes and nerve damage, small bowel transit time did not differ between liraglutide and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeSmall-bowel transit time
    Study

    n = 48

    Comparator
    Placebo
    Outcome group
    Gastrointestinal motility · Gastrointestinal
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide treatment reduced large bowel transit time (31.7%, p = 0.04) and decreased motility index (6.1%, p = 0.04) compared to placebo, whereas the groups did not differ in gastric emptying or small-bowel transit times.
    1 context sentence
    Summary · context
    A total of 48 adults with type 1 diabetes and confirmed distal symmetric polyneuropathy were randomised to receive liraglutide 1.8 mg/day or placebo for 26 weeks.
  5. 05HumanRandomized controlled trialSafety outcome

    In adults with type 1 diabetes and polyneuropathy, liraglutide increased postprandial fullness.

    In plain wordsIn adults with type 1 diabetes and nerve damage, liraglutide increased the feeling of fullness after meals.

    Peptide
    Liraglutide
    Outcome
    IncreasePostprandial fullness symptom score
    Study

    n = 48

    Comparator
    Placebo
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    1.8 mg/day · 26 weeksAs given in this study (human).

    Measurements

    Increase in postprandial fullness
    29%
    liraglutide

    Source sentences

    Summary
    Liraglutide increased postprandial fullness with 29% (p = 0.01).
    1 context sentence
    Summary · context
    A total of 48 adults with type 1 diabetes and confirmed distal symmetric polyneuropathy were randomised to receive liraglutide 1.8 mg/day or placebo for 26 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.